MARKET

DAWN

DAWN

Day One Biopharmaceuticals, Inc.
NASDAQ
8.12
-0.16
-1.93%
After Hours: 8.23 +0.11 +1.35% 17:26 03/26 EDT
OPEN
8.28
PREV CLOSE
8.28
HIGH
8.28
LOW
7.93
VOLUME
820.61K
TURNOVER
--
52 WEEK HIGH
18.07
52 WEEK LOW
7.88
MARKET CAP
823.00M
P/E (TTM)
-7.9274
1D
5D
1M
3M
1Y
5Y
1D
Day One Biopharm Is Maintained at Buy by Goldman Sachs
Dow Jones · 1d ago
Day One Biopharm Price Target Cut to $27.00/Share From $39.00 by Goldman Sachs
Dow Jones · 1d ago
Goldman Sachs Maintains Buy on Day One Biopharmaceutical, Lowers Price Target to $27
Benzinga · 1d ago
Weekly Report: what happened at DAWN last week (0317-0321)?
Weekly Report · 2d ago
Weekly Report: what happened at DAWN last week (0310-0314)?
Weekly Report · 03/17 09:03
Weekly Report: what happened at DAWN last week (0303-0307)?
Weekly Report · 03/10 09:04
Day One Biopharm Price Target Cut to $34.00/Share From $39.00 by JP Morgan
Dow Jones · 03/05 15:08
Day One Biopharm Is Maintained at Overweight by JP Morgan
Dow Jones · 03/05 15:08
More
About DAWN
Day One Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. Its product candidates include tovorafenib, pimasertib and the VRK1 program. The Company’s lead product candidate, tovorafenib, is an investigational, oral, brain-penetrant, highly selective type II RAF kinase inhibitor. The Company’s pipeline also includes pimasertib, an investigational, oral, highly selective small molecule inhibitor of mitogen-activated protein kinases 1 and 2 (MEK-1/-2). It has initiated an open-label, multicenter, phase Ib/IIa umbrella master trial, or FIRELIGHT-1, of tovorafenib as a monotherapy or in combination, which consists of two substudies. Substudy 1 is a phase IIa trial of tovorafenib as a monotherapy in patients 12 years and older.

Webull offers Day One Biopharmaceuticals Inc stock information, including NASDAQ: DAWN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DAWN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DAWN stock methods without spending real money on the virtual paper trading platform.